EA201991673A1 - Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации - Google Patents
Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализацииInfo
- Publication number
- EA201991673A1 EA201991673A1 EA201991673A EA201991673A EA201991673A1 EA 201991673 A1 EA201991673 A1 EA 201991673A1 EA 201991673 A EA201991673 A EA 201991673A EA 201991673 A EA201991673 A EA 201991673A EA 201991673 A1 EA201991673 A1 EA 201991673A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- immuno
- lab3
- radioactive isotope
- labeled radioactive
- antibodies
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title 1
- 238000012800 visualization Methods 0.000 title 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 2
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 238000012879 PET imaging Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457287P | 2017-02-10 | 2017-02-10 | |
| PCT/US2018/017525 WO2018148476A1 (en) | 2017-02-10 | 2018-02-09 | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991673A1 true EA201991673A1 (ru) | 2020-01-17 |
Family
ID=61244834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991673A EA201991673A1 (ru) | 2017-02-10 | 2018-02-09 | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
Country Status (18)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| IL322104A (en) | 2017-05-30 | 2025-09-01 | Bristol Myers Squibb Co | Treatment of lag-3 positive tumors |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| PH12021552675A1 (en) | 2019-05-13 | 2022-07-04 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20220152555A (ko) * | 2020-03-12 | 2022-11-16 | 비온드 바이오로직스 엘티디 | 증가된 안정성을 가진 쉐딩 차단제 |
| PE20230839A1 (es) | 2020-06-22 | 2023-05-19 | Ngm Biopharmaceuticals Inc | Agentes de union a lair-1 y metodos para su uso |
| US12447218B1 (en) * | 2021-02-09 | 2025-10-21 | Actinium Pharmaceuticals, Inc. | Radioconjugates directed to MHC-complexed antigens in cancer |
| CN115337413B (zh) * | 2022-08-08 | 2023-08-22 | 中国科学院近代物理研究所 | 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用 |
| KR102759386B1 (ko) * | 2022-08-11 | 2025-01-24 | 성균관대학교산학협력단 | 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| CN121127264A (zh) | 2023-03-13 | 2025-12-12 | 瑞泽恩制药公司 | 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合 |
| TW202535926A (zh) * | 2023-10-30 | 2025-09-16 | 美商再生元醫藥公司 | 穩定抗體配製物 |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| KR100257466B1 (ko) | 1994-05-06 | 2000-07-01 | 레지날드 쇼트버그 에스. 안토니우스-소도 | Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체 |
| WO1997003695A1 (en) | 1995-07-21 | 1997-02-06 | Applied Research Systems Ars Holding N.V. | Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein |
| US6524802B1 (en) * | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2006502091A (ja) | 2002-03-01 | 2006-01-19 | イミューノメディクス、インコーポレイテッド | クリアランス速度を高めるための二重特異性抗体点変異 |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1897548B2 (en) | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
| US7199064B2 (en) | 2003-09-08 | 2007-04-03 | Matsushita Electric Industrial Co., Ltd. | Plasma processing method and apparatus |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| WO2006049599A1 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy for atheromatous plaques using immune modulation |
| US20080260650A1 (en) | 2004-10-28 | 2008-10-23 | The General Hospital Corporation | Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8889100B2 (en) | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| WO2008124467A1 (en) | 2007-04-06 | 2008-10-16 | Macrocyclics | Bifunctional hydroxamic acid ligands and method of synthesis |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20090297439A1 (en) | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20120027055A (ko) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| PL3095871T3 (pl) | 2010-02-08 | 2019-10-31 | Regeneron Pharma | Mysz zawierająca wspólny łańcuch lekki |
| RU2613886C2 (ru) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения |
| KR20140014116A (ko) | 2010-12-20 | 2014-02-05 | 제넨테크, 인크. | 항-메소텔린 항체 및 면역접합체 |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| US10668162B2 (en) | 2012-01-06 | 2020-06-02 | Linxis B.V. | Method for preparing cell targeting conjugates, and the complexes obtained |
| WO2013138696A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| JP6242865B2 (ja) | 2012-05-01 | 2017-12-06 | ジェネンテック， インコーポレイテッド | 抗ｐｍｅｌ１７抗体および免疫複合体 |
| KR101718200B1 (ko) | 2012-05-21 | 2017-03-21 | 제넨테크, 인크. | 항-Ly6E 항체 및 면역접합체 및 사용 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014066733A2 (en) | 2012-10-25 | 2014-05-01 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2673583T3 (es) | 2013-02-28 | 2018-06-22 | National Cancer Center | Anticuerpo contra fibrina insoluble |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| WO2014159087A1 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
| EP2970474B1 (en) | 2013-03-14 | 2017-12-20 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| IL240838B (en) * | 2013-03-15 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Anti-3–lag binding proteins |
| WO2014200969A2 (en) | 2013-06-10 | 2014-12-18 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| HUE056325T2 (hu) | 2013-08-26 | 2022-02-28 | Biontech Res And Development Inc | SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN105658237B (zh) | 2013-10-21 | 2021-03-09 | 基因泰克公司 | 抗Ly6E抗体及使用方法 |
| KR102894975B1 (ko) | 2013-11-19 | 2025-12-04 | 프레닥스 에이비 | 인간화된 안티 칼리크레인-2 항체 |
| MA39095A1 (fr) | 2013-12-13 | 2018-08-31 | Genentech Inc | Anticorps et immunoconjugués anti-cd33 |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| MA39313B1 (fr) * | 2014-03-11 | 2018-12-31 | Regeneron Pharma | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2015140212A1 (en) | 2014-03-19 | 2015-09-24 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| EP2954933A1 (en) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| WO2015188934A1 (en) | 2014-06-10 | 2015-12-17 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2015191715A1 (en) | 2014-06-11 | 2015-12-17 | Genentech, Inc. | Anti-lgr5 antibodies and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| PL3177640T3 (pl) | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| TW201625690A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｃｌｌ－１抗體及免疫結合物 |
| EP3191518B1 (en) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| KR102508173B1 (ko) | 2014-09-12 | 2023-03-10 | 제넨테크, 인크. | 항-her2 항체 및 면역콘주게이트 |
| CA2983459C (en) | 2014-10-16 | 2023-11-07 | The University Of Melbourne | Imaging composition and uses thereof |
| EA037590B1 (ru) | 2014-11-25 | 2021-04-19 | Бристол-Майерс Сквибб Компани | Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| WO2016144873A2 (en) | 2015-03-06 | 2016-09-15 | Mayo Foundation For Medical Education And Research | Methods for cell labeling and medical imaging |
| NL2014423B1 (en) | 2015-03-09 | 2016-10-13 | Linxis B V | Method for removing weakly bound functional moieties from cell targeting conjugates. |
| WO2016172010A1 (en) | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN114853891A (zh) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| US20170097333A1 (en) | 2015-09-28 | 2017-04-06 | Merck Sharp & Dohme Corp. | Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents |
| EP3359573B1 (en) | 2015-10-01 | 2023-01-04 | The Whitehead Institute for Biomedical Research | Labeling of antibodies |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3377117A1 (en) | 2015-11-18 | 2018-09-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| IL262892B2 (en) | 2016-05-18 | 2024-04-01 | Boehringer Ingelheim Int | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
| HRP20210644T8 (hr) | 2016-05-19 | 2021-06-25 | Bristol-Myers Squibb Company | Imunomodulatori za pet-snimanje |
| AU2017278573A1 (en) | 2016-06-06 | 2019-01-03 | Linxis B.V. | Cell targeting conjugates |
| SI3472207T1 (sl) | 2016-06-20 | 2021-04-30 | F-Star Delta Limited | Vezavne molekule, ki vežejo PD-L1 in LAG-3 |
| PT3476399T (pt) | 2016-06-23 | 2022-05-31 | Jiangsu Hengrui Medicine Co | Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste |
| EP3474879A4 (en) | 2016-06-24 | 2020-05-06 | University of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3266465A1 (en) | 2016-07-06 | 2018-01-10 | Julius-Maximilians-Universität Würzburg | Immune complexes |
| US11633506B2 (en) | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| CA3031076C (en) | 2016-07-18 | 2023-10-03 | Wisconsin Alumni Research Foundation | Radiohalogenated agents for in situ immune modulated cancer vaccination |
| EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES |
| PL3515946T3 (pl) * | 2016-09-23 | 2022-11-07 | Regeneron Pharmaceuticals, Inc. | Przeciwciała anty-muc16 (mucyna 16) |
| EP4026849A1 (en) | 2016-09-26 | 2022-07-13 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors |
| WO2018128664A2 (en) | 2016-10-20 | 2018-07-12 | The University Of North Carolina At Chapel Hill | 18f-labeled compounds for pet imaging and uses thereof |
| EP4464334A3 (en) | 2016-11-07 | 2025-01-08 | VIDAC Pharma Ltd. | Use of compounds for treating hk2-expressing cancers |
| CN110382534B (zh) * | 2016-11-29 | 2023-05-09 | 里珍纳龙药品有限公司 | 治疗prlr阳性乳腺癌的方法 |
| US10736976B2 (en) * | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| CN110168105B (zh) | 2016-12-09 | 2024-05-24 | 瑞泽恩制药公司 | 用于对t细胞受体进行测序的系统和方法及其用途 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| SG11202002282TA (en) | 2017-09-20 | 2020-04-29 | Regeneron Pharma | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden |
-
2018
- 2018-02-09 BR BR112019016336-0A patent/BR112019016336A2/pt unknown
- 2018-02-09 CA CA3053348A patent/CA3053348A1/en active Pending
- 2018-02-09 IL IL313695A patent/IL313695A/en unknown
- 2018-02-09 US US15/892,440 patent/US10905784B2/en active Active
- 2018-02-09 MX MX2019009565A patent/MX2019009565A/es unknown
- 2018-02-09 KR KR1020247013269A patent/KR102813603B1/ko active Active
- 2018-02-09 WO PCT/US2018/017525 patent/WO2018148476A1/en not_active Ceased
- 2018-02-09 EP EP18706165.0A patent/EP3580238A1/en active Pending
- 2018-02-09 AU AU2018219909A patent/AU2018219909B2/en active Active
- 2018-02-09 SG SG11201907208XA patent/SG11201907208XA/en unknown
- 2018-02-09 IL IL268667A patent/IL268667B2/en unknown
- 2018-02-09 CN CN201880024346.1A patent/CN110650974B/zh active Active
- 2018-02-09 EA EA201991673A patent/EA201991673A1/ru unknown
- 2018-02-09 JP JP2019543051A patent/JP7167041B2/ja active Active
- 2018-02-09 KR KR1020197026079A patent/KR102660715B1/ko active Active
- 2018-02-09 MA MA047456A patent/MA47456A/fr unknown
- 2018-02-09 MA MA46814A patent/MA46814B2/fr unknown
- 2018-02-09 CN CN202410383516.2A patent/CN118557758A/zh active Pending
- 2018-02-09 MY MYPI2019004493A patent/MY200034A/en unknown
-
2019
- 2019-08-08 PH PH12019501837A patent/PH12019501837A1/en unknown
- 2019-08-09 CL CL2019002264A patent/CL2019002264A1/es unknown
- 2019-08-09 CO CO2019008675A patent/CO2019008675A2/es unknown
- 2019-08-09 MX MX2025004620A patent/MX2025004620A/es unknown
-
2020
- 2020-12-18 US US17/127,618 patent/US11511001B2/en active Active
-
2022
- 2022-10-25 US US18/049,609 patent/US20230270894A1/en active Pending
-
2025
- 2025-02-11 AU AU2025200923A patent/AU2025200923A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991673A1 (ru) | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации | |
| CL2019001483A1 (es) | Anticuerpos anti-pd-l1 radiomarcados para imágenes de inmuno-pet. | |
| MX2020000916A (es) | Anticuerpos anti-cd8 y usos de estos. | |
| JOP20200343A1 (ar) | بروتين ربط مولد ضد مضاد لـ steap1 | |
| SV2019005807A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| PL3662271T3 (pl) | System do określania obecności substancji będącej przedmiotem zainteresowania w próbce | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| EA201890383A1 (ru) | Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3) | |
| MX374853B (es) | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso. | |
| EA201791167A1 (ru) | Способы и композиции для мечения радиоактивным изотопомf биологических препаратов | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| MX2020002243A (es) | Anticuerpos utiles en diagnosis de cancer. | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| GB2522131A (en) | Isotopic labelling of proteins | |
| EA201991243A1 (ru) | Меченные радиоактивной меткой антитела против pd-l1 для иммуно-пэт визуализации | |
| CO2017007377A1 (es) | Antígenos recombinantes de giardia, purificación de anticuerpos policlonales igg e igy anti-giardia y detección de giardia | |
| MX2017008748A (es) | Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana. | |
| EA202090272A1 (ru) | Антитела к cd8 и пути их применения | |
| FR3028858B1 (fr) | Anticorps monoclonal specifique de borrelia crocidurae et une methode de diagnostic in vitro d'une fievre recurrente de borreliose | |
| TH1901003225A (th) | แอนติ-pd-l1 แอนติบอดีซึ่งติดฉลากกัมมันต์สำหรับทำให้เกิดภาพอิมมูโน-pet | |
| EA201790748A1 (ru) | НАБОР ДЛЯ ИЗМЕРЕНИЯ ТИТРА БЕЛКА, ВКЛЮЧАЮЩЕГО ЧЕЛОВЕЧЕСКИЙ Fc, С ПОМОЩЬЮ НЕПРЯМОГО ИФА, И СПОСОБ ИЗМЕРЕНИЯ ТИТРА БЕЛКА, ВКЛЮЧАЮЩЕГО ЧЕЛОВЕЧЕСКИЙ Fc, С ЕГО ИСПОЛЬЗОВАНИЕМ | |
| EP3383432A4 (en) | IGG SUB-TYPING TEST FOR IDENTIFICATION OF TRANSPLANTABLE TISSUE SAMPLES | |
| AR116101A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| EA202090071A1 (ru) | F-меченое соединение для диагностики рака предстательной железы и его применение |